Fulgent Genetics vs Grail
FLGT and GRAL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FLGT and GRAL compare
Grail is the larger company, worth 7.6 times as much as Fulgent Genetics ($5.2B against $679M).
Grail grew revenue faster over the last twelve months (17.5% versus 4.7% for Fulgent Genetics).
Fulgent Genetics keeps more of each dollar of sales as profit, with a net margin of −27.5% compared with −244% at Grail.
Grail scores higher on the StockData Score (10 against 8 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FLGT | GRAL |
|---|---|---|
| Size and price | ||
| Market cap | $679M | $5.2B |
| Share price | $24.66 | $115.89 |
| Change, 1 year | −15.2% | 36.7% |
| Change, 5 years | −73.8% | – |
| Beta (5Y) | 0.89 | 2.49 |
| Employees | 1,300 | 910 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.1× (better) | 31.1× |
| P/B | 0.7× (better) | 2.1× |
| FCF yield | −0.21% (better) | −6.0% |
| Fair value | $46.08 | – |
| Margin of safety | 46.5% | – |
| Growth | ||
| Revenue growth (TTM) | 4.7% | 17.5% (better) |
| Revenue growth, 5Y average | −5.2% | – |
| Profitability | ||
| Gross margin | 33.8% | – |
| Operating margin | −39.2% (better) | −347% |
| Net margin | −27.5% (better) | −244% |
| FCF margin | −0.42% (better) | −187% |
| Return on equity | −8.6% (better) | −17.3% |
| Return on invested capital | −12.0% (better) | −27.1% |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Interest coverage | −1307.9× | – |
| Current ratio | 5.34 | 8.93 (better) |
| Altman Z-score | 5.18 | 5.51 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 9.5% | – |
| Shareholder yield | 9.5% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 57.0% | 87.6% |
| Held by insiders | 39.5% | 11.0% |
| Insider net buying, 12 months | −$286K (better) | −$38.0M |
| Short interest, % of float | 12.1% | 20.1% |
Go deeper
- FLGT stock overview
- FLGT income statement
- FLGT valuation and score
- GRAL stock overview
- GRAL income statement
- GRAL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.